Orchard Therapeutics PLC (ORTX)
|Net Income (ttm)||-141.86M|
|Day's Range||0.98 - 1.08|
|52-Week Range||0.98 - 9.08|
|Price Target||10.31 (+921.0%)|
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinica... [Read more...]
Financial PerformanceFinancial Statements
According to 9 analysts, the average rating for ORTX stock is "Strong Buy." The 12-month stock price forecast is 10.31, which is an increase of 921.04% from the latest price.
Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatme...
Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and...
Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients
BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th Annua...
Are these $3 penny stocks worth buying in 2022? The post Top Penny Stocks to Buy Under $3?
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results ...
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy
BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available ...
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
Nine accepted abstracts demonstrate broad potential of the company's HSC gene therapy approach to treat severe neurodegenerative diseases and immunological disorders Nine accepted abstracts demonstrate ...
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future ...
Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively
BOSTON and LONDON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D Investor Event on Tue...
BOSTON and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Compensation Committee of Orchard's Board of Directors a...
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs
Orchard Therapeutics plc (NASDAQ: ORTX) and Pharming Group NV (NASDAQ: PHAR) have collaborated to research, develop, manufacture and commercialize OTL-105 for hereditary angioedema (HAE). OTL-105 is an ...
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Ge...
Highlights the broader potential of Orchard's ex vivo HSC gene therapy platform approach in new and larger indications
Orchard Therapeutics plc (NASDAQ: ORTX) has provided updates on the progress of its lead gene therapy programs targeting metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I Hurler syndrome ...
Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
Commercial Activities Advancing for Upcoming Launch of Libmeldy TM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany
Three years after receiving gene therapy from Orchard Therapeutics (NASDAQ: ORTX) in an early-stage clinical trial, 100% of patients with an inherited disease that damages the immune system were still a...
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
100% overall survival and ≥ 95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Ce...
Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support ...
MINNEAPOLIS--(BUSINESS WIRE)--Be The Match BioTherapies announced an expansion of their multi-year partnership with Orchard Therapeutics.
Shares of Orchard Therapeutics (NASDAQ:ORTX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 26.09% year over year to ($0.34), which beat the esti...
$150M Strategic Financing Supports Execution into the First Half of 2023